Traditional accuracy metrics no longer suffice for comparing diagnostic pathways for prostate cancer; new comparative performance metrics are needed that prioritize the overall benefit-to-harm ratio. Key performance metrics, such as biopsy efficiency, biopsy (grade) selectivity, and biopsy avoidance safety, enable meaningful patient-level comparisons across studies. Standardized benefit-to-harm metrics reporting enhances quality assurance, informs personalized diagnostics, and supports integration into clinical guidelines to improve the safety of prostate cancer diagnosis.
European urology oncology. 2026 Mar 17 [Epub ahead of print]
Anwar R Padhani, Sigrid Carlsson, Ola Bratt, Ivo G Schoots
Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK. Electronic address: ., Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Translational Medicine, Division of Urological Cancers, Lund University, Skåne University Hospital, Malmö, Sweden., Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Netherlands Cancer Institute, Amsterdam, The Netherlands.